Small molecule activation of the tumor suppressor kinase LKB1
Kretschmer, L. S.; Mitchell, D. C.; Liu, J.; Wang, L.; Wang, Z.; He, C.; Ding, L.; Adler, M.; Turnham, R. E.; Kellett, T.; Keith, A.; Hwang, Y. C.; Chan, G. K. L.; Li, W.; Ramamoorthi, R.; Lively, S.; Drakas, R. A.; Ramani, V.; Qing, T.; Verba, K. A.; Ostrem, J. M. L.; Beresis, R. T.; Gordan, J. D.
Show abstract
The ability to identify and target oncogenic signals has transformed clinical oncology. Drug development for targeted therapies has historically focused on the inhibition of oncogenic kinases and GTPases. However, many cancer patients do not benefit from targeted approaches because their tumors lack targetable mutations. Therapeutic augmentation of tumor suppressive signaling could be a viable alternative but poses challenges. Specifically, designing compounds capable of stimulating kinase activity is more structurally challenging than inhibitor design, and most kinases lack targetable allosteric pockets. Inactivation of the liver kinase B1 (LKB1) tumor suppressor kinase is associated with poor prognosis and therapeutic resistance. Thus, augmented LKB1 function could be beneficial for cancer patients whose tumors retain intact copies of the gene. LKB1 signals as part of an obligate trimer including the scaffolding protein Mouse protein-25 (MO25) and the pseudokinase (PSK) STE20-related kinase adapter protein (STRAD). As STRAD binds but does not metabolize ATP, it provides the opportunity for a novel activation strategy. We have developed STRAD-binding compounds capable of activating LKB1 and demonstrate the therapeutic benefits of LKB1 activation in a target-dependent manner within cancer cell lines.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Live-cell NanoBRET assay to measure AKT inhibitor binding to conformational states of AKT 96%
- Repurposing of the RIPK1 selective benzooxazepin-4-one scaffold for the development of a type-III LIMK1/2 inhibitor 95%
- Inhibition of a Selective SWI/SNF Function Synergizes with ATR Inhibitors in Cancer Cell Killing 95%
Similar papers in this journal
- An improved PDE6D inhibitor combines with Sildenafil to synergistically inhibit KRAS mutant cancer cell growth 97%
- DFG-1 residue controls inhibitor binding mode and affinity providing a basis for rational design of kinase inhibitor selectivity 96%
- Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease 96%
Similar papers in this journal
- Enhancing Intracellular Accumulation and Target Engagement of PROTACs with Reversible Covalent Chemistry 96%
- Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity 96%
- The Endo-GeneScreen Platform Identifies Drug-Like Probes that Regulate Endogenous Protein Levels within Physiological Contexts 95%
Similar papers in this journal
- A drug's most potent target is not necessarily the source of its anti-cancer activity 96%
- Catalytic domain plasticity of MKK7 reveals structural mechanisms of allosteric activation and new targeting opportunities 96%
- Targeting the PI5P4K lipid kinase family in cancer using novel covalent inhibitors 96%
Similar papers in this journal
- CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors. 95%
- Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer 95%
- A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.